Publication November 6, 2026

Pasireotide Featured in New Pediatric Gigantism Case Publication

A new publication referencing pasireotide was released on November 6, 2026. The case report, titled "Pediatric gigantism due to ectopic growth hormone releasing hormone secretion from a metastatic bronchial neuroendocrine tumor," appeared in JCEM Case Reports.

This publication documents a clinical case involving ectopic growth hormone releasing hormone secretion originating from a metastatic bronchial neuroendocrine tumor in a pediatric patient. The report was indexed under PubMed ID 42996503.

No specific findings, outcomes, or treatment results related to pasireotide are detailed in the available event data. The publication is noted here as a new addition to the medical literature involving this compound's clinical context.

Pasireotide remains an approved compound. Readers interested in its broader clinical background and regulatory status can consult the compound overview for additional context.

See the full pasireotide overview

Source: https://pubmed.ncbi.nlm.nih.gov/42996503/